Dr. Marianne Holm, MD, Ph.D. - VP, Infectious Diseases, Novo Nordisk Foundation

Dr. Marianne Holm, MD, Ph.D. is Vice President of the Infectious Diseases Program area, at the Novo Nordisk Foundation ( https://novonordiskfonden.dk/en/ ) where she is responsible for supporting the development and implementation of new strategic initiatives and research programs, and developing partnerships that contribute to the global visibility and impact of the foundation’s activities within Infectious Diseases, and this responsibility includes supporting multiple cross disciplinary initiatives in Antimicrobial Resistance (AMR).

Dr. Holm is a medical doctor and epidemiologist, who previously led the department of epidemiology and public health research at the International Vaccine Institute (IVI) in Seoul, where she was responsible for the coordination and implementation of several large development programs funded by the Fleming Fund, working with local governments and healthcare institutions to build capacity in AMR surveillance in low- and middle- income countries in the Asian region.

Prior to joining IVI in 2018, Dr. Holm worked for 4 years at the School of Public Health at the University of Hong Kong working in the health services research unit coordinating the School's evidence based practice education program.

Dr. Holm has been a member of the coordination group of the WHO Technical Advisory Group and Coordination Group on Vaccines and AMR. She is also a member of the Global Burden of Disease (GBD) Collaborator Network as well as the Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) network.

Dr. Holm received her MD and Ph.D. from University of Copenhagen and Master of Science (MSc), Epidemiology, London School of Hygiene and Tropical Medicine, U. of London.

IMPORTANT EPISODE LINK - Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) - https://gcgh.grandchallenges.org/challenge/innovations-gram-negative-antibiotic-discovery

The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) is tripartite initiative of the Novo Nordisk Foundation, the Bill & Melinda Gates Foundation and Wellcome Trust, that will focus on discovery of direct-acting small-molecule antibiotics with broad-spectrum activity against Enterobacteriaceae (a large family of Gram-negative bacteria that includes Salmonella, Escherichia coli, Shigella and Klebsiella), with Klebsiella spp. selected as an initial targeted pathogen. Klebsiella organisms can lead to a wide range of disease states, notably pneumonia, urinary tract infections, sepsis, meningitis, diarrhea, peritonitis and soft tissue infections. The program aims to address the lack of novel antibiotics for gram-negative bacteria and the public health threat posed by antimicrobial resistance (AMR).

#NovoNordiskFoundation #GramNegativeAntibioticDiscoveryInnovator #BillAndMelindaGatesFoundation #WellcomeTrust #AMR #AntimicrobialResistance #Enterobacteriaceae #Klebsiella #Salmonella #EscherichiaColi #Shigella #InfectiousDiseases #MarianneHolm #Vaccines #MultidrugEffluxPumps #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research